Browsing Tag
ArriVent BioPharma
2 posts
ArriVent shares plunge as FURVENT miss shifts attention to PACC lung cancer and ADC pipeline
ArriVent shares plunge after firmonertinib misses the FURVENT Phase 3 endpoint, putting its first-line exon 20 lung cancer strategy at risk.
InnoCare Pharma, ArriVent BioPharma initiate Phase 1b clinical trial in NSCLC
InnoCare Pharma, listed on both the Hong Kong Stock Exchange (HKEX: 09969) and the Shanghai Stock Exchange (SSE:…